您的位置: 首页 > 农业专利 > 详情页

TOP2A inhibition by temozolomide useful for predicting GBM patient's survival
专利权人:
Council of Scientific & Industrial Research
发明人:
Kumaravel, Somasundaram,Arimappamagan, Arivazhagan,Thennarasu, Kandavel,Hegde, Alangar Sathyaranjandas,Chandramouli, Ashwathnarayana Rao,Vani, Santosh,Kondaiah, Paturu,Manchanahalli Rangaswamy, Satyan
申请号:
AU2011306643
公开号:
AU2011306643A1
申请日:
2011.09.22
申请国别(地区):
AU
年份:
2013
代理人:
摘要:
The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充